| (Values in U.S. Thousands) | Sep, 2025 | Jun, 2025 | Mar, 2025 | Dec, 2024 | Sep, 2024 |
| Sales | 458,580 | 178,490 | 166,800 | 212,530 | 196,830 |
| Sales Growth | +156.92% | +7.01% | -21.52% | +7.98% | -1.43% |
| Net Income | 215,720 | -42,150 | -92,230 | -36,350 | -57,450 |
| Net Income Growth | +611.79% | +54.30% | -153.73% | +36.73% | -52.55% |
Apellis Pharmaceuticals Inc
(APLS)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
by (Cboe BZX)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
[[ item.lastPriceExt ]]
[[ item.priceChangeExt ]]
([[ item.percentChangeExt ]])
[[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Apellis Pharmaceuticals, Inc. is a clinical-stage biotech focused on the development of novel therapeutics, which work through the inhibition of the complement system, specially targeting the C3 protein of the complement system to treat autoimmune and inflammatory diseases.
Fiscal Year End Date: 12/31